KO Client VitriVax Closes Series A Financing Round
- KO Firm
- July 14, 2021
VitriVax, the developer of a novel stabilization and delivery platform for vaccines and therapeutics, has closed its first institutional financing round with Adjuvant Capital.
The Series A proceeds will be used to develop and commercialize a technology with the potential to eliminate barriers to global vaccine administration, extending their life-saving benefits to underserved populations and compressing multi dose regimens into a single shot, according to a press release.
“We could not be happier to partner with Adjuvant Capital as our lead investor to help us maximize the impact of VitriVax and our game-changing ALTA™ formulation platform,” VitriVax CEO Matt Raider said in the press release.
“Building on the early development of our technology at CU Boulder, with support from the Bill & Melinda Gates Foundation, we are excited to work alongside Adjuvant and its partners to further advance the platform and enable new and improved vaccines and therapeutics for high-value public health challenges.”
Read more about the financing.